Experimental 'Super-Universal' immune cells take on tough blood cancers
NCT ID NCT07153068
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new type of immune cell therapy called supCD7 CART cells in 12 adults with relapsed or refractory CD7-positive blood cancers (T-cell leukemia/lymphoma or acute myeloid leukemia). The cells are designed to target and kill cancer cells that carry the CD7 protein. Participants will receive chemotherapy before the cell infusion. The main goals are to check safety and see if the treatment can shrink or eliminate the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- super-universal CD7 CART cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could offer a new treatment option for people with hard-to-treat blood cancers that have come back after other therapies.
- What could go wrong
- This is a very early, small trial (only 12 people) to test safety and dosing. It may not work for everyone, and there are risks like severe immune reactions or side effects from the chemotherapy given beforehand.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Can a new drug combo outperform standard care for a tough blood cancer?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- New drug cocktail aims to stop leukemia return after transplant